11 completed, 3 recruiting, 3 terminated, 1 active not recruiting. 21 Phase 1, 5 Phase 2.
Follow Thymoma: new trials by email Literature Review of Thymoma trials Research Report on Thymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma STAR0602, Nivolumab - NSCLC, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 67 | 2026-11-18 | 2026-11-13 |
| Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma Cyclophosphamide, Fludarabine, EB-CAR30-NK - B2 Thymoma, Thymic Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-05-20 |
| CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors CD70-targeted CAR-T cells - Renal Cell Carcinoma (RCC), Lung Cancer | Phase 1 | Suspended | Chongqing Precision Biotech Co., Ltd | 90 | 2025-09-12 | 2026-09-11 |
| Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma cyclophosphamide, fludarabine, TNhYP218 CAR T Cells - Mesothelioma, Neoplasms | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-07-08 | 2026-11-05 |
| A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers KFA115, pembrolizumab - Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 126 | 2022-10-26 | 2026-10-20 |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S QBS10072S - Astrocytoma, Brain Cancer | Phase 1 | Completed | Quadriga Biosciences, Inc. | 15 | 2020-07-20 | 2023-01-18 |
| Thymectomy With and Without Povidone-iodine Pleural Lavage in Stage IVA Thymic Malignancies Intraoperative providone-iodine lavage - Stage IVA Thymoma | Phase 1 / Phase 2 | Withdrawn | Yale University | 2020-07-01 | 2022-07-25 | |
| 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours 177Lu-DOTA-TATE + olaparib - Clinical Trial, Phase I, Neuroendocrine Tumors | Phase 1 | Completed | Vastra Gotaland Region | 18 | 2020-04-23 | 2026-04-14 |
| Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Bosutinib, Pemetrexed - Carcinoma, Non-Small-Cell Lung, Mesothelioma | Phase 1 | Completed | Nagla Abdel Karim | 6 | 2019-12-10 | 2022-06-14 |
| Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Vorolanib, Nivolumab - Thymic Carcinoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 88 | 2018-07-10 | 2024-10-08 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors XmAb20717 - Melanoma, Breast Carcinoma | Phase 1 | Completed | Xencor, Inc. | 150 | 2018-07-10 | 2022-12-01 |
| Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer Pembrolizumab - Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 37 | 2017-12-06 | 2026-07-16 |
| Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343) - Neoplasms | Phase 1 | Completed | Bayer | 173 | 2017-05-26 | 2022-06-30 |
| Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide - Lung Cancer, Esophageal Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 10 | 2010-12-07 | 2020-03-03 |
| Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies palifosfamide-tris - Malignancy, Cancer | Phase 1 | Completed | Alaunos Therapeutics | 22 | 2010-12-01 | 2026-09-29 |
| Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas Celebrex, Tumor cell vaccine - Mesolthelioma, Esophageal Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 44 | 2010-12-01 | 2019-12-03 |
| A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies PXD101with cisplatin+doxorubicin+cyclophosphamide - Thymoma, Thymic Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 26 | 2010-03-04 | 2017-08-10 |
| Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Esophageal sparing IMRT - Non Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 | Completed | Duke University | 24 | 2009-09-11 | 2020-04-02 |
| Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma Gleevec (imatinib) - Thymic Carcinoma | Phase 1 | Completed | Indiana University | 11 | 2006-04-01 | 2014-06-03 |
| Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions recombinant adenovirus-hIFN-beta - Cancer | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 2003-04-01 | 2020-05-13 |
Showing 20 of 21. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (10) · Lung Neoplasms (7) · Neoplasms (7) · Ovarian Neoplasms (7) · Esophageal Neoplasms (6) · Mesothelioma (6) · Small Cell Lung Carcinoma (6) · Thymus Neoplasms (6) · Uterine Cervical Neoplasms (6) · Carcinoma, Renal Cell (5) · Melanoma (5) · Pancreatic Neoplasms (5) · Prostatic Neoplasms (5) · Stomach Neoplasms (5)
Hemic and Lymphatic Diseases (21) · Lymphatic Diseases (21) · Neoplasms by Histologic Type (21) · Neoplasms by Site (21) · Neoplasms, Complex and Mixed (21) · Thoracic Neoplasms (21) · Lung Diseases (15) · Respiratory Tract Diseases (15) · Respiratory Tract Neoplasms (15) · Thymus Neoplasms (15) · Neoplasms (14) · Neoplasms, Glandular and Epithelial (12) · Adenoma (10) · Bronchial Neoplasms (10) · Carcinoma, Bronchogenic (10)
Cyclophosphamide (3) · Celecoxib (2) · Nivolumab (2) · fludarabine (2) · pembrolizumab (2) · AP 1903 reagent (1) · Cisplatin (1) · FANG vaccine (1) · Gemcitabine (1) · Imatinib Mesylate (1) · Pemetrexed (1) · anetumab ravtansine (1) · bosutinib (1) · entinostat (1) · isophosphamide mustard (1)
National Cancer Institute (NCI) (5) · Abramson Cancer Center at Penn Medicine (1) · Alaunos Therapeutics (1) · Bayer (1) · Beijing Biotech (1) · Chongqing Precision Biotech Co., Ltd (1) · Duke University (1) · Indiana University (1) · M.D. Anderson Cancer Center (1) · Nagla Abdel Karim (1) · National Institutes of Health Clinical Center (CC) (1) · Novartis Pharmaceuticals (1) · Quadriga Biosciences, Inc. (1) · Vanderbilt-Ingram Cancer Center (1) · Vastra Gotaland Region (1)
United States (16) · China (3) · Australia (2) · Canada (2) · France (2) · Italy (2) · Singapore (2) · South Korea (2) · Spain (2) · Belgium (1) · Germany (1) · Hong Kong (1) · Japan (1) · Netherlands (1) · Sweden (1)
Arun Rajan, M.D. (2) · David S Schrump, M.D. (2) · Anne S Tsao (1) · Christopher Kelsey, MD (1) · Daniel H. Sterman, MD (1) · Donglai Lv, MD (1) · Kathryn Beckermann, MD (1) · Nagla Karim, MD (1) · Patrick Loehrer (1) · Raffit Hassan, M.D. (1) · Shivaani Kummar, MD (1) · Zequn Tang, MD (1)
PMID 20068553, PMID 21502553, PMID 25189481, PMID 34114913, PMID 34829796, PMID 42459653
2016 (1), 2019 (1)